2,4-Dichloropyrimidine → 2-{4-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-phenyl}-N-ethyl-propionamide
反応式
[CH2:1]([NH:3][C:4](=[O:19])[CH:5]([C:7]1[CH:12]=[CH:11][C:10]([CH:13]2[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]2)=[CH:9][CH:8]=1)[CH3:6])[CH3:2].[Cl:20][C:21]1[N:26]=[C:25](Cl)[CH:24]=[CH:23][N:22]=1>CN(C=O)C>[Cl:20][C:21]1[N:26]=[C:25]([N:16]2[CH2:17][CH2:18][CH:13]([C:10]3[CH:11]=[CH:12][C:7]([CH:5]([CH3:6])[C:4]([NH:3][CH2:1][CH3:2])=[O:19])=[CH:8][CH:9]=3)[CH2:14][CH2:15]2)[CH:24]=[CH:23][N:22]=1参加物
4
実験手順
355 μL (2.53 mmol) TEA are added to a mixture of 600 mg (2.30 mmol) N-ethyl-2-(4-piperidin-4-yl-phenyl)-propionamide (VI.1) and 377 mg (2.53 mmol) 2,4-dichloro-pyrimidine in 25 mL DMF. The mixture is stirred for 3 h at rt. Subsequently the solvent is removed in vacuo and the residue is purified using reversed phase HPLC (water, 0.3% NH4OAc/acetone) to yield the desired product.